Since the invasion of Ukraine, hundreds of companies have announced a pause or withdrawal of businesses in Russia. Drugmakers Eli Lilly, Novartis and AbbVie are …

After neatly wrapping up concerns over a series of Emgality ads last month, Eli Lilly is back in hot water with the FDA’s Office of …

While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and …

For years, drugmakers have targeted “weaknesses” in the U.S. healthcare system to reap dividends on older meds, The House Oversight Committee said Friday. The “outrageous …

The second regulatory shoe has finally dropped for AbbVie, Pfizer and Eli Lilly amid the safety review of JAK inhibitors for inflammatory diseases. But confirmed …

Amid reports that COVID-19 antibody treatments from Regeneron and Eli Lilly lose their effectiveness against the omicron variant, GlaxoSmithKline and Vir Biotechnology said on Tuesday …

On the centennial of the discovery of insulin, China decided a round of price cuts on the diabetes therapy is due. As a result, foreign …

Three months after earning an approval to treat chronic heart failure with their SGLT2 inhibitor Jardiance, Eli Lilly and Boehringer Ingelheim have posted new data …

Chasing rivals from AstraZeneca and Eli Lilly/Boehringer Ingelheim, Johnson & Johnson’s Invokana is vying for a piece of the lucrative heart failure market. J&J’s Type …

Heart failure and chronic kidney disease often go hand in hand. And when they do, the risk of death and hospitalization increase. A new analysis …